Photo from wikipedia
Key Points Ixazomib, cyclophosphamide, and dexamethasone combination achieved hematologic response in 63% of newly diagnosed AL amyloidosis patients. The regimen is characterized with a favorable adverse event profile and should… Click to show full abstract
Key Points Ixazomib, cyclophosphamide, and dexamethasone combination achieved hematologic response in 63% of newly diagnosed AL amyloidosis patients. The regimen is characterized with a favorable adverse event profile and should be explored in other combinations.
Keywords:
cyclophosphamide dexamethasone;
trial ixazomib;
ixazomib cyclophosphamide;
phase trial;
dexamethasone previously;
amyloidosis
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!